Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 2;24(21):e202300498.
doi: 10.1002/cbic.202300498. Epub 2023 Sep 13.

Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs

Britton K Ody  1 , Jing Zhang  1 , Sydney E Nelson  2 , Yayun Xie  1 , Ruochuan Liu  1 , Cayden J Dodd  2 , Savannah E Jacobs  1 , Savannah L Whitzel  2 , Leighan A Williams  2 , Samer Gozem  3 , Mark Turlington  2 , Jun Yin  1
Affiliations

Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs

Britton K Ody et al. Chembiochem. .

Abstract

Target validation is key to the development of protein degrading molecules such as proteolysis-targeting chimeras (PROTACs) to identify cellular proteins amenable for induced degradation by the ubiquitin-proteasome system (UPS). Previously the HaloPROTAC system was developed to screen targets of PROTACs by linking the chlorohexyl group with the ligands of E3 ubiquitin ligases VHL and cIAP1 to recruit target proteins fused to the HaloTag for E3-catalyzed ubiquitination. Reported here are HaloPROTACs that engage the cereblon (CRBN) E3 to ubiquitinate and degrade HaloTagged proteins. A focused library of CRBN-pairing HaloPROTACs was synthesized and screened to identify efficient degraders of EGFP-HaloTag fusion with higher activities than VHL-engaging HaloPROTACs at sub-micromolar concentrations of the compound. The CRBN-engaging HaloPROTACs broadens the scope of the E3 ubiquitin ligases that can be utilized to screen suitable targets for induced protein degradation in the cell.

Keywords: Cereblon; HaloPROTAC; HaloTag; PROTAC; ubiquitin.

PubMed Disclaimer

References

    1. None
    1. J. Lu, Y. Qian, M. Altieri, H. Dong, J. Wang, K. Raina, J. Hines, J. D. Winkler, A. P. Crew, K. Coleman, C. M. Crews, Chem. Biol. 2015, 22, 755-763;
    1. D. P. Bondeson, A. Mares, I. E. Smith, E. Ko, S. Campos, A. H. Miah, K. E. Mulholland, N. Routly, D. L. Buckley, J. L. Gustafson, N. Zinn, P. Grandi, S. Shimamura, G. Bergamini, M. Faelth-Savitski, M. Bantscheff, C. Cox, D. A. Gordon, R. R. Willard, J. J. Flanagan, L. N. Casillas, B. J. Votta, W. den Besten, K. Famm, L. Kruidenier, P. S. Carter, J. D. Harling, I. Churcher, C. M. Crews, Nat. Chem. Biol. 2015, 11, 611-617;
    1. A. C. Lai, C. M. Crews, Nat. Rev. Drug Discovery 2017, 16, 101-114;
    1. K. M. Sakamoto, K. B. Kim, A. Kumagai, F. Mercurio, C. M. Crews, R. J. Deshaies, Proc. Natl. Acad. Sci. USA 2001, 98, 8554-8559.

Publication types

LinkOut - more resources